Drug-specific and time-dependent risks of bacterial infection among patients with rheumatoid arthritis who were exposed to tumor necrosis factor alpha antagonists.
about
Infections requiring hospitalization in the abatacept clinical development program: an epidemiological assessment.A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registriesJAK inhibition for the treatment of rheumatoid arthritis: a new era in oral DMARD therapy.TNF-α antagonist use and risk of hospitalization for infection in a national cohort of veterans with rheumatoid arthritisThe comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agentsRisk of hospitalised infection in rheumatoid arthritis patients receiving biologics following a previous infection while on treatment with anti-TNF therapy.Comparative safety of infliximab and etanercept on the risk of serious infections: does the association vary by patient characteristics?Physicians' explanations for apparent gaps in the quality of rheumatology care: results from the US Medicare Physician Quality Reporting System.Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases.Tumor necrosis factor inhibitors and infection complications.Use of a disease risk score to compare serious infections associated with anti-tumor necrosis factor therapy among high- versus lower-risk rheumatoid arthritis patients.Use of biologics in rheumatoid arthritis: current and emerging paradigms of care.Harms of TNF inhibitors in rheumatic diseases: a focused review of the literature.Systematic review of tumor necrosis factor inhibitor discontinuation studies in rheumatoid arthritis.A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy.Anti-TNF therapy in Jordan: a focus on severe infections and tuberculosis.Characteristics and outcomes of rheumatoid arthritis patients who started biosimilar infliximab.Incidence of comprehensive hospitalization due to infection, cardiovascular disease, fractures, and malignancies in patients with rheumatoid arthritis.Comparison of the risk of infections in different anti-TNF agents: a meta-analysis.Rheumatoid arthritis triple therapy compared with etanercept: difference in infectious and gastrointestinal adverse events.Comparative Rates of Serious Infections Among Patients With Systemic Lupus Erythematosus Receiving Immunosuppressive Medications.Comparative Risk of Hospitalized Infection Associated With Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare.Risk of Subsequent Infection Among Patients Receiving Tumor Necrosis Factor Inhibitors and Other Disease-Modifying Antirheumatic Drugs.Risk of hospitalized infection among rheumatoid arthritis patients concurrently treated with a biologic agent and denosumab.Risk of tuberculosis comparison in new users of antitumour necrosis factor-α and with existing disease-modifying antirheumatic drug therapy.Treatment of Collagen-Induced Arthritis Using Immune Modulatory Properties of Human Mesenchymal Stem Cells.
P2860
Q33923452-71D2646C-FD26-412F-8B09-CDEF1A6FB26CQ34216770-E5818E4E-B056-4AF9-A71E-2FAD4F21AD61Q34276089-674608E9-B810-4AB5-94EC-2850D840E455Q34792330-4F185F07-DB28-45A8-8CDD-192C9D8993F2Q35082559-48B6530D-467C-4D0F-B960-39ABBA8B2F9EQ35636624-671CC3BB-0354-40C7-B2BB-49716757E74FQ35899264-DC56FD59-0B9A-43C1-8897-2DA557FA7373Q36150089-5E41414A-E86A-4347-B43B-8AF7AB7D6DD7Q36191250-5B429D26-B1A6-4C9A-B0D9-60D64FA29702Q36806922-34F85E8D-B454-4D69-A354-978D61014FCEQ36942914-AEE978B4-337B-4A0E-B355-8D4EDA4EC58EQ37000165-2081BBEE-1936-485A-BF27-2FA980FE83D8Q37189376-83020F10-8335-4E3B-A295-865DB896DD0DQ37567461-9B6BEEE0-DD62-4F83-B918-E0E33A03DC3BQ37604531-B510EC85-CEDE-4F2D-8CCB-53A291E919B0Q37729543-2F9338E0-BAA2-4829-B535-E3BCAAB3DEBAQ38953729-886C5439-9841-4EAE-A97B-204130F8A9EEQ40061090-1DD88B84-ED6E-4E51-B8AD-64FE85E26DBAQ40345791-0D1118C1-E55A-4B71-AB55-01C7015D1A60Q40403655-BD04C10D-ECD1-4F91-BA5B-1ADCEB3E011AQ40553708-09DFBA5C-3A7F-43D6-AEA1-C6444BAB5B3CQ40598586-6E468BCC-8269-45F4-B3A4-708897654FCBQ41005556-84DFC3A7-3E49-4031-8B7C-A823B1B327C3Q41362251-23C7E4CC-49B9-4C1B-BECC-DE36A7AC4AB9Q47717769-59BE79F0-0AB9-4DC2-A017-465C6E7A6936Q48240482-A61C7B01-AE5A-48B2-A886-DDC0186A2BCD
P2860
Drug-specific and time-dependent risks of bacterial infection among patients with rheumatoid arthritis who were exposed to tumor necrosis factor alpha antagonists.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Drug-specific and time-depende ...... osis factor alpha antagonists.
@en
type
label
Drug-specific and time-depende ...... osis factor alpha antagonists.
@en
prefLabel
Drug-specific and time-depende ...... osis factor alpha antagonists.
@en
P2093
P2860
P356
P1476
Drug-specific and time-depende ...... osis factor alpha antagonists.
@en
P2093
Aiyuan Xie
Carolyn Martin
Jeffrey R Curtis
Kenneth G Saag
Nivedita Patkar
P2860
P304
P356
10.1002/ART.23050
P577
2007-12-01T00:00:00Z